Navigation Links
Adynxx Completes Enrollment in Phase 1 Clinical Study of Lead Therapeutic for Treatment of Pain, AYX1
Date:8/7/2012

SAN FRANCISCO, Aug. 7, 2012 /PRNewswire/ -- Adynxx, a clinical stage pharmaceutical company developing a first-in-class platform of therapeutics to address pain at its molecular roots, announced today the completion of enrollment in the Phase 1 clinical study in healthy volunteers of its lead investigational drug candidate for the prevention of acute and chronic post-surgical pain, AYX1.

"The Adynxx therapeutic platform – a novel approach to treating and preventing pain – has the potential to transform pain management," said Dennis Podlesak, chairman of the Adynxx board of directors. "The clinical development of this breakthrough technology is being driven by an accomplished management team that has a track record of success that includes building successful biotech companies and attaining multiple new drug approvals. The Adynxx team is well positioned to achieve our goal of developing these exciting new treatment options for preventing pain."

The 30 subject, dose-escalating study is currently evaluating AYX1 in five cohorts of healthy volunteers. Later this year, Adynxx plans to move into a proof-of-concept Phase 2 clinical study assessing the ability of a single administration of AYX1 at the time of surgery to reduce acute pain, prevent the transition to persistent post-surgical pain and consequently improve functional recovery.

"Despite many years of investigation and development, effective relief of post-surgical pain remains a challenge for the millions of patients who undergo surgery every year," said Rick Orr, president and chief executive officer of Adynxx. "Given the urgent need for new treatment options for post-surgical pain, we are excited to have advanced the AYX1 development program at such a rapid pace since the company's founding.  With enrollment complete, we look forward to receiving and evaluating the unblinded safety data later this quarter.  This will allow us to initiate a Phase 2 efficacy study in the coming months."

Added Donald C. Manning, M.D., Ph.D., chief medical officer of Adynxx, "Therapeutics currently available to physicians and patients address pain as a symptom and often only as it arises. While we believe that these established therapeutics have a place in treatment of pain, we are interested in developing transformative options for those who seek to treat pain as a preventable and ultimately curable disease."

The AYX therapeutic platform was designed by Julien Mamet, Ph.D., founder and chief scientific officer of Adynxx, to specifically address a significant unmet need in pain therapy: providing long-term pain relief with a one-time treatment. It acts by simultaneously neutralizing complementary and redundant molecular mechanisms that maintain pain over time.  Long-term efficacy of AYX1 after a single administration has been demonstrated in a variety of preclinical pain and functional assessment models.  In addition to AYX1, Adynxx is advancing a pipeline of therapeutics for treatment of other indications, including chronic lower back pain and intractable neuropathic and inflammatory pain syndromes.

About Adynxx

Adynxx, located in San Francisco, California, is a clinical stage pharmaceutical company developing a transformative technology platform addressing pain at its molecular roots - preventing the development of pain following surgery or trauma and resolving established chronic pain syndromes.  Adynxx's unique approach is to transform pain management by approaching pain as a disease rather than a symptom. 

Adynxx's lead compound, AYX1, is an investigational drug designed to prevent acute post-surgical pain and the transition to persistent or chronic pain with a single administration at the time of surgery.  Adynxx has completed enrollment in a Phase 1 clinical trial of AYX1 and plans to initiate a Phase 2 study of AYX1 in Q4 2012.  AYX2, intended to resolve multiple forms of chronic lower back pain, is currently in pre-clinical development along with additional compounds intended to target a range of intractable neuropathic and inflammatory pain syndromes. For more information, visit www.adynxx.com

Media Contact:

David Schull or Ian Stone
Russo Partners
(858) 717-2310
(619) 308-6541
david.schull@russopartnersllc.com
ian.stone@russopartnersllc.com


'/>"/>
SOURCE Adynxx
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. HeartWare Completes Acquisition Of World Heart Corporation
2. Haemonetics Completes Acquisition of Palls Transfusion Medicine Business
3. Hologic Completes Acquisition Of Gen-Probe
4. United Seating & Mobility Completes Acquisition of Active American Mobilitys Rehab Division
5. United Seating & Mobility Completes Acquisition of Active American Mobility
6. Omeros Successfully Completes Preclinical Studies of OMS824 for Schizophrenia and Phase 1 Clinical Trial Preparations Underway
7. Mindray Medical Completes Acquisition of Dragonbios Orthopedics Business
8. Henry Schein Completes Three Acquisitions To Advance Strategic Plan
9. SJF Ventures Completes Oversubscribed Series A Round for BioSurplus
10. Terumo Completes U.S. Patient Enrollment in the OSPREY Trial to Evaluate the MISAGO Self-expanding Stent
11. Ultra Clean Holdings, Inc. Completes Strategic Merger with Advanced Integration Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/19/2017)... 19, 2017  Mako Medical Laboratories partnered with Secretary ... Family Assistance Fund (MFA) to bring 140 soldiers back ... with their families one last time before being deployed. ... travel and logistics needed for these soldiers. "Mako Medical ... their families. We just wish we could bring them ...
(Date:7/14/2017)... 13, 2017 It should come as no surprise ... is in the midst of a crippling opioid epidemic. According ... the number of overdose deaths from opiate-based medications has quadrupled, ... a million dead from 2001 to 2015". During this time, ... has similarly quadrupled, drawing a compelling link between prescription and ...
(Date:7/12/2017)... , July 12, 2017 CarpalAID is a revolutionary ... braces or surgery. Carpal tunnel syndrome affects more than ... at twice the rate of men. The common methods of treating ... mobilization with uncomfortable hand braces or gloves. ... CarpalAID is a clear patch ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... July 21, 2017 , ... The Karen Miller Agency, a ... in the greater Birmingham area, is joining the Chris Hammond Youth Foundation in ... the region. , The Chris Hammond Youth Foundation maintains athletic facilities in rural ...
(Date:7/21/2017)... ... July 21, 2017 , ... Thomas Jefferson University ... , was awarded a $300,000 grant from The Pew Center for Arts & ... ambiguity and the recognition of one’s own limits among health professions students. ...
(Date:7/21/2017)... ... 21, 2017 , ... The Margarian Law Firm has filed a class ... ale for allegedly containing no ginger. Dr. Pepper produces the “Canada Dry” brand of ... Margaryan alleges Canada Dry Ginger Ale claims on its bottle that it is made ...
(Date:7/21/2017)... ... July 21, 2017 , ... MedMatchPlus+ has ... chances of acceptance to a residency in a United States hospital. Being accepted ... the U.S. , According to data released by the ECFMG®, every year, 50 ...
(Date:7/21/2017)... ... July 21, 2017 , ... West Dermatology is pleased to announce the ... July 17, 2017, Ms. Vu will join West Dermatology’s large network of medical and ... skin cancer , and more. She graduated from the University of Florida College ...
Breaking Medicine News(10 mins):